Table 2. Clinical and treatment-related characteristics of adult HIV patients on ART at University of Gondar Comprehensive Specialized Hospital between January 1, 2015, and December 31, 2018.
Variable | Category | Frequency | Percentage (%) |
---|---|---|---|
Baseline CD4 count | ≤200 | 221 | 41.62 |
201–350 | 117 | 22.03 | |
>350 | 193 | 36.35 | |
Baseline WHO stage | Stage I | 238 | 44.82 |
Stage II | 101 | 19.02 | |
Stage III | 119 | 22.41 | |
Stage IV | 73 | 13.75 | |
Last known WHO stage | Stage I | 301 | 56.69 |
Stage II | 136 | 25.61 | |
Stage III | 58 | 10.92 | |
Stage IV | 36 | 6.78 | |
Past OIs | Yes | 225 | 42.37 |
No | 306 | 57.63 | |
CPT | Yes | 366 | 68.93 |
No | 165 | 31.07 | |
IPT | Yes | 123 | 23.16 |
No | 408 | 76.84 | |
Baseline Functional status | Working | 374 | 70.43 |
Ambulatory | 121 | 22.79 | |
Bedridden | 36 | 6.78 | |
Type of regimen at start | 1e (TDF-3TC-EFV) | 473 | 89.08 |
1c (AZT-3TC-NVP) | 39 | 7.34 | |
1d/1f/1g | 19 | 3.58 | |
Baseline BMI | <18.5 | 170 | 32.02 |
18.5–24.9 | 314 | 59.13 | |
≥25 | 47 | 8.85 | |
Current TB status | Positive | 30 | 5.65 |
Negative | 501 | 94.35 |
1d = AZT-3TC-EFV,1f = TDF-3TC-NVP,1g = ABC- 3TC-EFV, BMI = body mass index, OI = opportunistic infection, CPT = cotrimoxazole preventive therapy, IPT = isoniazid preventive therapy